MMRF’s MyDRUG Platform Trial Aims For Efficiency In Testing Treatments For Myeloma Mutations
Executive Summary
The adaptive trial design will help test smaller subpopulations and could lead to more effective and cost-efficient treatment strategies.
You may also be interested in...
Multiple Myeloma: Pricing And Reimbursement Challenges Escalate Even As Blockbusters Go Generic
As new drugs move into earlier lines of therapy for use in combination and for longer periods, payers are growing more sensitive to myeloma therapies' costs in the US and major ex-US markets.
Woodcock Hopes I-SPY 2 Trial Is 'Blazing The Trail' For Future Adaptive Design Uptake
CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them.
Genomics-Driven Trials Built To Be Fast And Flexible
Pioneering enrollment strategies are coupled with adaptive statistical designs in the next wave of basket trials from NCI, ASCO and Novartis.